Email this article CURRENT POSSIBILITIES OF TREATMENT FOR VISCERAL METASTASES IN PATIENTS WITH METASTATIC CASTRATION-REFRACTORY PROSTATE CANCER
- Authors: Govorov A.V.1, Moiseenko T.N.1
-
Affiliations:
- Moscow State University of Medicine and Dentistry named after A.I. Evdokimov
- Issue: Vol 9, No 2 (2013)
- Pages: 53-56
- Section: PROSTATE CANCER
- Published: 30.06.2013
- URL: https://oncourology.abvpress.ru/oncur/article/view/94
- DOI: https://doi.org/10.17650/1726-9776-2013-9-2-53-56
- ID: 94
Cite item
Full Text
Abstract
Medications increasing the survival of patients with metastatic castration-refractory prostate cancer (CRPC) are lacking today. In the past 3 years, in the pharmaceutical market there have been a few novel drugs to treat progressive prostate cancer. Abiraterone acetate is an androgen synthesis inhibitor, which is also used to increase the survival of patients with metastatic CRPC that progresses after chemotherapy. The results of treatment for metastatic CRPC depend on a number of factors. Visceral metastases are poor predictors of the course of the disease. The results of abiraterone acetate treatment were analyzed in CRPC patients with visceral metastases.
About the authors
A. V. Govorov
Moscow State University of Medicine and Dentistry named after A.I. Evdokimov
Author for correspondence.
Email: alexgovorov@newmail.ru
Department of Urology Russian Federation
T. N. Moiseenko
Moscow State University of Medicine and Dentistry named after A.I. Evdokimov
Email: alexgovorov@newmail.ru
Department of Urology Russian Federation
References
Supplementary files
